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Abstract
Aims—This study dealt with the effect of chronic ethanol administration on hemodynamic responses
elicited by α2-adrenergic (α-methyldopa) or I1-imidazoline (rilmenidine) receptor activation in
telemetered female rats.
Main methods—The effects of α-methyldopa or rilmenidine on blood pressure (BP), heart rate
(HR) and their variability were investigated in rats that received liquid diet without or with ethanol
(5% w/v) for 12 weeks. To evaluate the effect of each drug on cardiovascular autonomic control (BP
and HR variability) in the absence or presence of ethanol, three time-domain indices of hemodynamic
variability were measured: (i) standard deviation of mean arterial pressure (SDMAP), (ii) standard
deviation of beat-to-beat intervals, and (iii) root mean square of successive differences in R-R
intervals.
Key findings—In liquid diet-fed control rats, i.p. rilmenidine (600 μg/kg) or α-methyldopa (100
mg/kg) reduced BP along with decreases and increases, respectively, in HR. Both drugs had no effect
on HR variability but reduced BP variability (SDMAP), suggesting a reduced vasomotor sympathetic
tone. Ethanol feeding attenuated reductions in BP and SDMAP evoked by α-methyldopa but not by
rilmenidine.
Significance—We conclude that chronic ethanol preferentially compromises α2- but not I1-
receptor-mediated hypotension in female rats probably via modulation of vasomotor sympathetic
activity. These findings highlight the adequacy of rilmenidine use to lower BP in hypertensive
alcoholic females.
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The centrally acting antihypertensive agent clonidine, an imidazoline derivative, acts primarily
within the rostral ventrolateral medulla (RVLM) of the brainstem to reduce central sympathetic
outflow. Clonidine hypotension has been initially attributed to activation of central α2 receptors
(Timmermans and Van Zwieten, 1982). However, Bousquet et al. (1984,1992) proposed the
Author for correspondence: Abdel A. Abdel-Rahman, Ph.D., Department of Pharmacology, School of Medicine, East Carolina University,
Greenville, NC 27834. Tel. (252) 744-3470; Fax (252) 744-3203; Email: abdelrahmana@ecu.edu.
Dr. M. M. El-Mas is on a sabbatical leave from the Department of Pharmacology, Faculty of Pharmacy, University of Alexandria, Egypt
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Life Sci. Author manuscript; available in PMC 2010 January 16.
Published in final edited form as:
Life Sci. 2009 January 16; 84(3-4): 111–118. doi:10.1016/j.lfs.2008.11.006.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
existence of nonadrenergic “imidazoline” receptors in the RVLM, which are specifically
sensitive to imidazolines and are involved in the hypotensive and sympathoinhibitory effects
of clonidine and related drugs. Further research resulted in the introduction of the second-
generation centrally acting imidazolines, rilmenidine and moxonidine. Both drugs have more
selectivity for I1 than for α2 sites (Ernsberger et al., 1993; Chan et al., 1996) and elicit effective
reductions in BP in controlled trials (Dupuy et al., 2000). The relatively lower affinity of
rilmenidine and moxonidine, compared with clonidine, to α2 sites has been suggested as the
reason for their lesser side effects such as sedation and dry mouth (van Zwieten, 1997).
Our previous studies have shown that ethanol adversely affects the BP lowering effect of
centrally acting drugs. Importantly, the nature and magnitude of the interaction of ethanol with
antihypertensive drugs appears to be quite variable and depends primarily on factors such as
whether these drugs act peripherally or centrally, the brainstem receptor involved (α2 vs. I1),
and the regimen of ethanol administration (acute vs. chronic). In early studies, we reported that
acutely administered ethanol compromises hypotension of central origin (e.g. clonidine) but
not peripherally mediated hypotension (e.g. hydralazine) (Abdel-Rahman, 1989). Because
clonidine exhibits almost similar affinities at α2 and I1 receptors, subsequent studies
investigated the hemodynamic interaction of ethanol with clonidine-related drugs with
selective agonistic activity at either receptor site. Ethanol was found to counteract the
hypotensive and sympathoinhibitory effects of rilmenidine but not α-methylnorepinephrine,
selective I1 and α2 agonists, respectively. These findings suggested a preferential interaction
of ethanol with central pathways involved in I1-receptor mediated hypotension (El-Mas and
Abdel-Rahman, 1999a,b). On the other hand, long-term exposure to ethanol attenuates
centrally-evoked hypotension regardless of the receptor (α2 or I1) involved (El-Mas and Abdel-
Rahman, 2003, 2004). Because all previous studies that investigated the interaction of ethanol
with centrally-evoked hypotension were undertaken in male rats, it remains unclear whether
ethanol similarly interacts with I1- and α2-receptor-mediated hypotension in the female
population.
The present study was undertaken to evaluate the effect of chronic (12 weeks) ethanol feeding
on hypotensive responses caused by selective activation of the I1 (rilmenidine) or α2 (α-
methyldopa) receptor in telemetered female rats. Changes in hemodynamic (BP and HR)
variability, as measured by time-domain analysis (Stein et al., 1994; Sgoifo et al., 1997; El-
Mas and Abdel-Rahman, 2003, 2004), were also determined to assess the role of cardiovascular
autonomic control in the interaction. These experimental studies are clinically important
because while it is known that ethanol intake results in inadequate BP control in treated
hypertensive patients (Volicer et al., 1978; Puddey et al., 1987), very few studies evaluated the
interaction between ethanol and antihypertensive medications in females.
Materials and Methods
Female Sprague-Dawley rats (9-10 weeks; 190-225 g; Harlan, Indianapolis, IN) were used in
the present study. Upon arrival, rats were housed individually in standard plastic cages and
allowed free access to water and Purina chow and were maintained on a 12-12-h light-dark
cycle with light off at 7:00 p.m. The room temperature was maintained at 22±1°C. After one-
week acclimatization, rats were fed a standard Lieber-DeCarli high protein liquid diet (Dyets
Inc., Bethlehem, PA) for another week before ethanol feeding. Rats received the diet daily at
8:30 a.m. The experimental procedures were performed in accordance with the principles and
guidelines of the Canadian Council on Animal Care and were approved by the Institutional
Animal Care and Use Committee.
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Ethanol feeding
Two groups of female rats (n=6-7) matched for body weight were used in the present study.
Rats in the first group were provided ad libitum standard Lieber-DeCarli high protein liquid
diet (Lieber and DeCarli, 1982) containing 5% w/v ethanol (36 % of total caloric intake) as
described in our previous studies (El-Mas and Abdel-Rahman, 2004). The second group of rats
was pair-fed and received isocaloric amount of dextrin/maltose (89.6 g/l) in place of ethanol,
which allowed similar nutrient intake and fluid consumption to that of ethanol fed rats. Fresh
diets were prepared every other day and stored in the refrigerator until dispensed. Rats were
maintained on ethanol or control diet for 12 weeks.
Telemetry system
The telemetry system (Data Sciences Int., St. Paul, MN) used in this study has been described
in our previous studies (El-Mas and Abdel-Rahman, 2003, 2004). The system consists of 5
major components: (i) implantable transmitter unit for measurement of BP, (ii) radio receiver
to receive telemetered signals, (iii) ambient pressure monitor to measure absolute atmospheric
pressure, (iv) consolidation matrix to multiplex multiple cage signals to the computer, and (v)
a PC-based data acquisition system to process signals. The implanted sensor consisted of a
fluid-filled catheter (0.7 mm diameter, 15 cm long, Model TA11PA-C40) connected to a highly
stable low-conductance strain-gauge pressure transducer, which measured the absolute arterial
pressure relative to a vacuum, and a radio-frequency transmitter. The tip of the catheter was
filled with a viscous gel that prevented blood reflux and was coated with an antithrombogenic
film to inhibit thrombus formation and maintain patency. The distal 1 cm of the catheter
consisted of a thin walled thermoplastic membrane while the remainder of the catheter was
composed of a thick-walled low-compliance urethane. The implants (2.5 cm length and 1.2 cm
diameter) weighed 9 g and had a typical battery life of 6 months. A radio receiver platform
(RLA1010, Data Sciences Int.) connected the radio signal to digitized input that was sent to a
dedicated personal computer (Compaq, Pressario 9548). Arterial pressures were calibrated by
using an input from an ambient-pressure monitor (C11PR, Data Sciences Int.).
Transmitter implantation
The method described in our previous studies (El-Mas and Abdel-Rahman, 2003, 2004) was
adopted. The rats were anesthetized with i.p injection of a mixture of ketamine (90 mg/kg;
Ketaject) and xylazine (10 mg/kg; Xyla-ject). The abdomen was opened with a midline incision
(4 cm). Another incision (1.5 cm) was made along the inner thigh to expose the femoral artery.
The abdominal wall was pierced with a large bore syringe needle (15 gauge) from the femoral
side into the peritoneal cavity. The implant body was placed in the peritoneal cavity and the
catheter (15 cm) was passed caudally through the syringe needle into the thigh area. A 5-cm
portion of the catheter was inserted into the femoral artery and secured in place with sutures.
The abdominal muscle was closed with non-absorbable suture incorporating the implant suture
rib with alternating stitches. The skin (abdomen and thigh) was closed with surgical clips. Each
rat received a subcutaneous injection of the analgesic ketorolac tromethamine (2 mg/kg;
Toradol) and an intramuscular injection of 60,000 U of penicillin G benzathine and penicillin
G procaine in an aqueous suspension (Durapen). Individual rat cages were placed on the top
of the radio receivers and all data were collected using a computerized data acquisition system
(Dataquest ART, Data Sciences Int.). The system is designed to cycle from animal to animal.
Transmitter implantation was performed 9 weeks after ethanol or control diet feeding. Rats
were left for 3 additional weeks before starting the experiment (i.e. saline, α-methyldopa or
rilmenidine administration).
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Hemodynamic effects of α-methyldopa or rilmenidine
In this experiment we investigated the influence of chronic ethanol feeding on acute
hemodynamic effects of α-methyldopa or rilmenidine. Therefore, we measured BP, HR, and
their variability in conscious telemetered female rats after 12 weeks of ethanol feeding before
and for 7 hr after a single i.p. injection of saline (1 ml/kg), α-methyldopa (100 mg/kg), or
rilmenidine (600 μg/kg) at 3 days intervals. These doses of α-methyldopa and rilmenidine have
been shown to produce comparable falls in BP (El-Mas and Abdel-Rahman, 2004), which was
important for data interpretation. Waveforms of BP for each rat was sampled at a rate of 500
Hz for 10 s every 10 min. Changes in mean arterial pressure (MAP) and HR from baseline
values in pair-fed rats receiving liquid diet with or without ethanol (5%, w/v) were averaged
in 20-min blocks (i.e. the average of two successive measurements) for analysis as in our
previous studies (El-Mas and Abdel-Rahman, 2003, 2004).
Time-domain analyses
Three time-domain parameters were employed to measure hemodynamic variability as
described in previous studies including ours (Stein et al., 1994; Sgoifo et al., 1997; El-Mas and
Abdel-Rahman, 2003). The standard deviation of the mean arterial pressure (SDMAP) was
taken as a measure of BP variability. HR variability was determined by computing the standard
deviation of beat-to-beat intervals (SDRR) and the root mean square of successive beat-to-beat
differences in R-R interval durations (rMSSD). The R-R intervals were computed from the HR
values (i.e. the reciprocal of HR in msec) as in our previous studies (El-Mas and Abdel-
Rahman, 2003). Our previous studies and others have shown that the time-domain indices of
BP and HR variability correlate well with the frequency-domain measurements (Stein et al.,
1994; Sgoifo et al., 1997; El-Mas and Abdel-Rahman, 2000). The SDRR is comparable to the
total power of the spectrum of R-R variability, which measures the overall autonomic balance
of the heart. The rMSSD correlates with the high frequency power of the spectrum and,
therefore, more specifically quantifies the vagal influence on HR variability (Stein et al.,
1994; Sgoifo et al., 1997). Changes from baseline values evoked by each treatment (saline, α-
methyldopa or rilmenidine) in the short-term variability of MAP and HR were calculated by
averaging each 1-hr values (i.e. 6 successive measurements at 10 min intervals) of SDMAP,
SDRR and rMSSD for a total of 7 hr as described in our previous studies (El-Mas and Abdel-
Rahman, 2003, 2004). Baseline values of different hemodynamic variables were taken as the
average of the 3-hr period (9 am to 12 pm) that preceded drug treatments.
Measurement of plasma ethanol concentration
A blood sample was taken from each rat at the end of the 12-week period of the study and
blood ethanol content was determined by the enzymatic method as in our previous studies (El-
Mas and Abdel-Rahman, 2003, 2004).
Drugs
α-Methyldopa (Sigma Chemical Co., St. Louis, MO), Ketaject (ketamine), Xyla-ject (xylazine)
(Phoenix Pharmaceuticals Inc., St Joseph, MI), Toradol (ketorolac tromethamine, Abbott Labs,
Chicago, IL), Durapen (Penicillin G benzathine and penicillin G procaine, Vedco Inc.,
Overland Park, KS), and ethanol (Midwest Grain Products Co., Weston, MO) were purchased
from commercial vendors. Rilmenidine dihydrogen phosphate was a gift from Servier
Pharmaceutical Co., France.
Data and statistical analyses
All values are expressed as means±S.E.M. To obtain a measure of the cumulative BP effect of
rilmenidine or α-methyldopa, the area under the curve (AUC, mm Hg.hr) was calculated for
individual experiments using trapezoidal integration (Graph pad prism, version 3.0). The
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repeated measures analysis of variance (ANOVA) followed by a Newman-Keuls post-hoc test
was used to analyze the effects of ethanol feeding on hemodynamic responses to rilmenidine
or α-methyldopa. These analyses were performed by SAS software Release 6.04 (SAS Institute
Inc., Cary, NC) as in our previous studies (El-Mas and Abdel-Rahman, 2003). Probability
levels less than 0.05 were considered significant.
Results
Baseline data
As shown in Table 1, prior to the administration of saline, α-methyldopa or rilmenidine,
baseline BP, HR, and their variability indices (SDMAP, SDRR, and rMSSD) in ethanol (5%
w/v, 12 weeks) and pair-fed control rats were not statistically different. Blood ethanol
concentrations measured 12 weeks after ethanol feeding (5%) amounted to 151±14 mg/dl.
Effect of ethanol feeding on hemodynamic responses elicited by α-methyldopa
The time-course effects of α-methyldopa on BP, HR, and their time-domain variability indices
in female telemetered rats treated chronically with ethanol (5% w/v) for 12 weeks or their
control counterparts are shown in figures 1 and 2. Compared with the corresponding control
(saline) values, α-methyldopa (100 mg/kg, i.p.) produced significant reductions in MAP in
control rats that started at 60 min, and reached its peak (-15.2±2.5 mmHg) at 140 min. α-
Methyldopa hypotension started to dissipate after 5 hr but remained significantly lower than
corresponding values observed in control (liquid diet-fed) rats that received saline instead of
α-methyldopa (Fig. 1A). The HR showed significant increases by α-methyldopa in control rats
during the first 2 hr and subsided towards control (saline-treatment) levels thereafter (Fig. 1B).
The BP variability (SDMAP) was significantly reduced by α-methyldopa at 4 and 5 hr (Fig.
2A) whereas indices of HR variability, SDRR or rMSSD, were not affected (Fig. 2B, C).
In ethanol-fed rats, the tachycardic effect of α-methyldopa was preserved (Fig. 1B) whereas
the reduction in BP was attenuated for at least 3 hr compared with the effect of α-methyldopa
when given to pair-fed (control) female rats (Fig. 1A). Further, ethanol feeding significantly
attenuated the α-methyldopa-induced reduction in BP variability (Fig. 2A). Compared with
saline treatment, α-methyldopa elicited significant reductions in rMSSD in ethanol-fed rats at
2 and 3 hr (Fig 2C).
Effect of ethanol feeding on hemodynamic effects of rilmenidine
Figures 3 and 4 show the effects of chronic ethanol feeding on hemodynamic responses elicited
by rilmenidine in telemetered female rats. In pair-fed control rats, rilmenidine (600 μg/kg i.p.)
produced significant reductions in BP that peaked at 60 min (-17.6±1.6 mmHg) and continued,
with a lesser magnitude, for approximately 4 hr (Fig. 3A). Significant reductions in HR (for 2
hr, Fig. 3B) and SDMAP (at 4 hr, Fig. 4A) were also evident after rilmenidine administration
in pair-fed rats, compared with corresponding control (saline) values. In ethanol-fed rats, the
hypotensive action of rilmenidine was attenuated, compared with the hypotensive response
observed in pair-fed rats during the first hour of the study followed by slight increases thereafter
(Fig. 3A). The effects of rilmenidine on hemodynamic variability were not altered by ethanol
feeding, except for a significant reduction in rMSSD at 2 hr (Fig. 4).
The AUC of the cumulative BP effect caused by α-methyldopa or rilmenidine over the entire
7 hr period in rats treated with or without ethanol is shown in figure 5. The AUC of the
hypotensive effect of α-methyldopa was reduced by more than 40% (P<0.05) in ethanol-fed
compared with corresponding values in pair-fed controls (Fig. 5A). In contrast, the AUC of
the hypotensive response elicited by rilmenidine in the two groups of rats was not statistically
different (Fig. 5B).
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Discussion
Reported findings on acute and chronic effects of ethanol on hypotension elicited by clinically
prescribed medications may not appropriately be extrapolated to the female population for two
reasons. First, most of the reported studies have been undertaken in males (e.g. El-Mas and
Abdel-Rahman, 1999a, 1999b, 2003, 2004). Second, experimental and clinical studies have
demonstrated gender difference in the BP responses to ethanol (El-Mas and Abdel-Rahman,
1999c; Tobe et al., 2006). In the present study we investigated the influence of long-term
ethanol treatment on hemodynamic responses elicited by rilmenidine or α-methyldopa in
female rats. Rilmenidine, like moxonidine, has emerged as a second-generation centrally acting
antihypertensive agent and is regarded a viable replacement for the first-generation drugs
clonidine and α-methyldopa (van Zwieten, 1997; Dupuy et al., 2000). Two important findings
are reported here. First, chronic ethanol administration attenuated the hypotensive effect of α-
methyldopa and had no influence on the hypotension elicited by rilmenidine in female rats.
Second, the vascular sympathetic tone appears to play a critical role in the ethanol-α2-receptor
interaction since α-methyldopa-evoked reduction of BP variability was virtually abolished by
ethanol. These findings suggest that in randomly cycling female rats, ethanol feeding interrupts
central α2A but not I1 receptor signaling. Although these studies were conducted in
normotensive rats, the findings highlight the possibility that in female hypertensive individuals
who are regular alcohol users, rilmenidine represents a better choice, than α-methyldopa, for
the treatment of hypertension.
The present study revealed some principal differences in the hemodynamic profiles of
rilmenidine and α-methyldopa in liquid diet-fed female rats. Although the magnitude of the
hypotensive effect of the two drugs was comparable, the BP response to methyldopa was
generally delayed in onset and of longer duration. This has been traditionally related to the
view that α-methyldopa hypotension depends on its degradation in central neurons into α-
methylnorepinephrine, which is the ultimate mediator of the hypotensive action (Sweet,
1984). Another important aspect of the hemodynamic differences between rilmenidine and α-
methyldopa pertains to their effect on HR; decrease and increase, respectively. The bradycardic
effect of rilmenidine is consistent with its ability to reduce central sympathetic outflow (van
Zwieten, 1997). The paradoxical increase in HR by α-methyldopa, on the other hand, cannot
be considered as a compensatory baroreflex response to the evoked hypotension because the
increase in HR rapidly developed (within 20 min) after α-methyldopa administration and
preceded the fall in BP as showed in this study and others (van der Maas et al., 1986).
Alternatively, it has been suggested that the tachycardia is a peripherally mediated effect and
involves direct activation of cardiac β-adrenoceptors following the conversion of α-methyldopa
into to α-methyldopamine in cardiac sympathetic neurons (van der Maas et al., 1986). Pertinent
to this view also is the finding that α-methyldopa elicits no tachycardia when administered
centrally (van der Maas et al., 1986). Interestingly, in contrast to its tachycardic effect seen in
rats, α-methyldopa produces bradycardia in humans (van Zwieten et al., 1984) and other animal
species such as dogs (Lokhandwala et al., 1976) and rabbits (Badoer et al., 1983). The
bradycardic action of α-methyldopa, unlike the tachycardia, is entirely of central origin and
has a similar time course to that of the fall in BP (Lokhandwala et al., 1976; Badoer et al.,
1983). Although discrepancies in biosynthetic enzymes in cardiac sympathetic neurons have
been implicated in the species-related differences in the HR response to α-methyldopa (van
der Maas et al., 1986), the exact mechanism that underlies the tachycardic response in rodents
remains unclear and warrants further investigation.
The main objective of the current investigation was to evaluate whether chronically
administered ethanol influences similarly or differently the α2- and I1-receptor-mediated
hemodynamics in female rats. To accomplish this goal, we investigated the effect of ethanol
(5% w/v in liquid diet for 12 weeks) on the hemodynamic responses elicited by selective
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activation of I1 (rilmenidine) or α2 (α-methyldopa) receptors. The results showed that ethanol
preferentially affected the hemodynamic actions of the two drugs. Most notable, ethanol
significantly attenuated the α-methyldopa-evoked hypotension in contrast to no effect on
rilmenidine-evoked hypotension. Such discrepancy in the effect of ethanol became more
evident after analyzing the AUC of the hypotensive response by either hypotensive agent over
the entire 7 hr period of the study. The reason for this receptor-dependent effect of ethanol on
centrally evoked hypotension is not clear. Nonetheless, the preferential attenuation by ethanol
of the hypotensive response elicited by α-methyldopa may relate to the ability of ethanol to
diminish central α2-adrenoceptor sensitivity (Szmigielski et al., 1989) and to reduce α2 receptor
density in the nucleus tractus solitarius (El-Mas and Abdel-Rahman, 2001a), a major
neuroanatomical target for α-methyldopa (Kubo and Misu, 1981). Also, it is possible that
chronic accumulation of acetaldehyde, the metabolic product of ethanol, may interfere with
the degradation pathway of α-methyldopa (Collins et al., 1990), which mediates its hypotensive
effect. The latter possibility seems unlikely in our model system because the tachycardic
response elicited by α-methyldopa, which reflects the cardiac effect of the active metabolite
α-methyldopamine (van der Maas et al., 1986), was not influenced by chronic ethanol
administration (Fig. 1B). Whether chronic exposure to ethanol modifies the signaling and/or
density of I1 receptor in BP controlling nuclei of the brainstem has not been investigated.
Nonetheless, the lack of ethanol effect on the cumulative hypotensive response elicited by
rilmenidine over the 7 hr observation period seems to argue against this possibility. Together,
our findings suggest that in female rats, ethanol feeding interacts in a receptor-dependent
manner with neuronal pathways involved in the elicitation of centrally-evoked hypotension.
Time-domain analysis of hemodynamic variability was employed in the present study to reveal
changes in cardiovascular autonomic control and their possible contribution to the
hemodynamic interaction between ethanol and centrally acting hypotensive drugs. It has been
established from time- or frequency-domain studies that sympathoinhibition contributes to the
reduction in hemodynamic variability that parallels centrally-evoked hypotension (Elghozi et
al., 1991; Janssen et al., 1991; Tulen et al., 1993). Also, the reduced BP variability produced
by rilmenidine in hypertensive humans coincides with a predominant reduction in BP
fluctuations in the mid-frequency range (0.1 Hz), which reflects sympathoinhibition (Girard
et al., 1995). Along this line, the current demonstration that the hypotensive effect of α-
methyldopa or rilmenidine was accompanied by a reduction in the variability of BP (SDMAP)
but not HR (SDRR or rMSSD) points out to a selective inhibitory effect of the two drugs on
vascular, but not cardiac, sympathetic activity. Given that ethanol significantly attenuated the
depressant effect of α-methyldopa, but not rilmenidine, on BP variability, it is conceivable that
ethanol might have acted selectively to induce functional changes in central pathways
implicated in the sympathoinhibotry response to α2 receptor activation.
The variability of adjacent inter-beat intervals (rMSSD) is an important determinant of the
heart function as it largely reflects cardiac vagal activity (Stein et al., 1994; Sgoifo et al.,
1997). Neither rilmenidine nor α-methyldopa affected rMSSD in control (liquid diet fed)
female rats suggesting that the vagal cardiomotor activity was preserved in the presence of
these drugs. It was only in ethanol-fed rats, however, that the two hypotensive drugs elicited
significant reductions in rMSSD early during the course of their administration (see Figs. 2C,
5C). Considering that the reduction in rMSSD was not associated with any changes in SDRR,
this may infer a shift in the cardiac sympathovagal balance towards sympathetic dominance.
Although the underlying mechanism remains to be investigated, the reduction in rMSSD
evoked by centrally acting drugs in the presence of ethanol might be attributed to the combined
confounding effects of these intervening drugs on cardiovascular autonomic control.
Comparing the results of this study and our previous study (El-Mas and Abdel-Rahman,
2004) revealed important gender-related differences in the ethanol interaction with centrally
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acting antihypertensive agents. Whereas the attenuation of the hypotensive effect of α-
methyldopa caused by ethanol occurs in both genders, the rilmenidine-evoked hypotension
was compromised by ethanol in male (El-Mas and Abdel-Rahman, 2004) and not in female
rats (this study). Another difference relates to the ability of ethanol to attenuate the reduction
in BP variability evoked by α-methyldopa but not rilmenidine in female rats (this study) in
contrast to selectively attenuating the reduced BP variability caused by rilmenidine in the male
rat (El-Mas and Abdel-Rahman, 2004). These discrepancies in the hemodynamic effects of
ethanol cannot be accounted for by differences in the amounts or duration of ethanol
consumption because rats in both studies received ethanol for a period of 12 weeks and
exhibited similar blood ethanol levels. One considerable factor, however, may relate to the fact
that normotensive female rats were used in the present study in contrast to spontaneously
hypertensive male rats in our previous study (El-Mas and Abdel-Rahman, 2004). It is possible,
therefore, that the cardiovascular structural, autonomic, and hormonal alterations that
characterize hypertension (Biaggioni, 2003; Laurent et al., 2005) might be responsible for the
contrasting hemodynamic effects of ethanol in the present and previous studies (El-Mas and
Abdel-Rahman, 2004). We are not aware of any study that evaluated the interaction of ethanol
with selective α2/I1 receptor agonists in the normotensive male rat. In addition to the effect of
hypertension, sex (El-Mas and Abdel-Rahman, 1999c; Tobe et al., 2006) and the hormonal
modulation of the α2/I1 receptor binding activity (Karkanias et al., 1997; Piletz and Halbreich,
2000) are other potential factors that might also contribute to the contrasting effects of ethanol
on hypotension of central origin. More studies are clearly needed to investigate these
possibilities.
It is important to comment on the role of HR in the hemodynamic interaction between ethanol
and centrally acting drugs. Consistent with previous findings (El-Mas and Abdel-Rahman,
2001c, 2004), baseline HR was not affected by ethanol feeding. The comparison of HR values
in ethanol-fed and pair-fed control rats prior to the administration of α-methyldopa or
rilmenidine revealed no significant differences (see Table 1). Chronic ethanol also failed to
alter the HR response to rilmenidine (bradycardia) or α-methyldopa (tachycardia). Similar
observations were seen when both ethanol and rilmenidine were administered acutely (El-Mas
and Abdel-Rahman, 1999a). It is unlikely, therefore, that HR responses might have contributed
to the differential interaction of ethanol with the hypotensive effect of the two drugs is not
likely. This view is bolstered by our previous finding that ethanol attenuation of the hypotensive
effect of α-methyldopa in SHRs despite-ethanol evoked a reduction in the associated
tachycardia (El-Mas and Abdel-Rahman, 2004). Together, these findings argue against a
significant role for HR changes in the antagonistic BP interaction between ethanol and centrally
acting antihypertensive agents.
The present findings highlight a compromising effect of chronic ethanol administration on α-
methyldopa-evoked hypotension in female rats. This effect of ethanol seems to be
preferentially directed against α2–adrenergic receptor signaling because the I1-mediated
hypotension was not influenced by chronic ethanol administration. We further demonstrate
that the increase in vascular sympathetic activity is critical to the interaction of ethanol with
central α2-receptor-containing neuronal pools. Although these findings were generated in
normotensive rats, they may bear clinical relevance to the inadequacy of BP control in treated
hypertensive patients who are regular alcohol users (Volicer et al., 1978; Puddey et al.,
1987). Although our studies were conducted in normotensive rats, the findings infer that
rilmenidine and possibly related selective I1-receptor agonists (e.g. moxonidine) might
constitute a better choice, than α-methyldopa, for BP control in hypertensive females who are
regular users of alcohol. Moreover, because ethanol counteracted the reductions in BP
variability caused by α-methyldopa, but not by rilmenidine, the latter might be more
advantageous in the management of ventricular and vascular hypertrophy in female alcohol
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users. Notably, reduction in BP variability by centrally acting drugs contributes to the
regression of cardiovascular hypertrophy (Timio et al., 1987; Kohno et al., 1990).
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Figure 1.
Effect of chronic feeding of ethanol (5% w/v, 12 weeks) or control liquid diet on changes in
mean arterial pressure (MAP) and heart rate (HR) evoked by α-methyldopa (100 mg/kg i.p.)
in conscious telemetered female rats. Values are means±S.E.M. of 6-7 observations. *
and #P<0.05 versus corresponding saline and α-methyldopa (control) values, respectively.
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Figure 2.
Effect of chronic feeding of ethanol (5% w/v, 12 weeks) or control liquid diet on changes in
the variability indices of mean arterial pressure (SDMAP) and heart rate (standard deviation
of beat-to-beat intervals, SDRR, and the root mean square of successive beat-to-beat
differences, rMSSD) evoked by α-methyldopa (100 mg/kg i.p.) in conscious telemetered
female rats. Values are means±S.E.M. of 6-7 observations. * and #P<0.05 versus corresponding
saline and α-methyldopa (control) values, respectively.
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Figure 3.
Effect of chronic feeding of ethanol (5% w/v, 12 weeks) or control liquid diet on changes in
mean arterial pressure (MAP) and heart rate (HR) evoked by rilmenidine (600 μg/kg i.p.) in
conscious telemetered female rats. Values are means±S.E.M. of 6-7 observations. *
and #P<0.05 versus corresponding saline and rilmenidine (control) values, respectively.
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Figure 4.
Effect of chronic feeding of ethanol (5% w/v, 12 weeks) or control liquid diet on changes in
the variability indices of mean arterial pressure (SDMAP) and heart rate (standard deviation
of beat-to-beat intervals, SDRR, and the root mean square of successive beat-to-beat
differences, rMSSD) evoked by rilmenidine (600 μg/kg i.p.) in conscious telemetered female
rats. Values are means±S.E.M. of 6-7 observations. *P<0.05 versus corresponding saline
values.
El-Mas and Abdel-Rahman Page 15
Life Sci. Author manuscript; available in PMC 2010 January 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
Bar graphs showing the area under the curve of the hypotensive effect of i.p. α-methyldopa
(100 mg/kg, panel A) or rilmenidine (600 μg/kg, panel B) in conscious telemetered female rats
treated chronically with ethanol (5% w/v, 12 weeks) or control liquid diet. Values are means
±S.E.M. of 6-7 observations. * and #P<0.05 versus corresponding saline and control (α-
methyldopa, panel A; rilmenidine, panel B) values, respectively.
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Table 1
Baseline hemodynamic values of mean arterial pressure (MAP, mmHg), heart rate (HR, beats/min), MAP variability
(SDMAP, mmHg), standard deviation of R-R intervals (SDRR, msec), and root mean square of successive beat-to-
beat differences (rMSSD, msec).
Parameter Control Ethanol
MAP
 Pre-saline 98.1±4.2 97.0±3.1
 Pre-α-methyldopa 101.8±3.7 96.9±3.3
 Pre-rilmenidine 104.6±3.1 101.1±3.7
HR
 Pre-saline 367.7±23.4 346.3±10.1
 Pre-α-methyldopa 356.7±11.5 345.3±9.1
 Pre-rilmenidine 359.1±8.1 349.0±10.9
SDMAP
 Pre-saline 5.11±0.23 6.21±0.60
 Pre-α-methyldopa 5.27±0.43 5.60±0.74
 Pre-rilmenidine 5.36±0.41 5.99±0.66
SDRR
 Pre-saline 11.29±1.41 13.11±0.52
 Pre-α-methyldopa 9.53±1.57 11.51±1.22
 Pre-rilmenidine 11.94±1.31 13.28±1.64
rMSSD
 Pre-saline 5.44±0.64 4.92±0.32
 Pre-α-methyldopa 5.24±0.93 4.96±0.51
 Pre-rilmenidine 6.35±0.65 5.95±0.77
Values are means±SEM of 6-7 observations.
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